Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06558539
PHASE3

Tibial Nerve Stimulation for Post-BPH Overactive Bladder

Sponsor: Qing Yuan

View on ClinicalTrials.gov

Summary

A single-center, randomized, parallel-controlled design. Approximately 90 cases of persistent overactive bladder symptoms post benign prostatic hyperplasia surgery are expected to be enrolled. The study participants will be randomly assigned to three groups, with 30 participants in each group.

Official title: Study on the Efficacy of Wearable Transcutaneous Tibial Nerve Stimulation for Persistent Overactive Bladder Symptoms Post Benign Prostatic Hyperplasia Surgery

Key Details

Gender

MALE

Age Range

50 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2024-09

Completion Date

2025-02

Last Updated

2024-08-16

Healthy Volunteers

No

Interventions

DEVICE

Transcutaneous Tibial Nerve Stimulation(TTNS)

Participants in this group will discontinue all relevant medications (e.g., β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs) at least 14 days before signing the informed consent and will not use these medications during the study period. They will receive treatment solely with wearable transcutaneous tibial nerve stimulation.

COMBINATION_PRODUCT

Combination Therapy

Participants in this group will continue their prescribed medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration unchanged throughout the study. In addition to the standard medication therapy, participants will receive wearable transcutaneous tibial nerve stimulation using a wearable device

DRUG

Standard Medication Therapy

Participants in this group will maintain their usual medication regimen, which may include β3-adrenergic agonists, non-selective β-adrenergic agonists, or anticholinergic drugs, with dosages and administration remaining consistent throughout the study. No additional interventions will be provided.